Aurie Receives FDA De Novo Grant for First Automated Safely Reusable Intermittent Urinary Catheter System
Company announces appointment of
The Aurie System includes: a 100-use no-touch intermittent catheter; a portable catheter washer-disinfector; and pre-packaged supply pods. The system delivers single-use no-touch catheter features at a fraction of the cost. Rigorous testing—from microbiology to human factors—demonstrated the reasonable assurance of safety and effectiveness for the intended use of the Aurie System+ and set the standard for all reusable catheter systems to come.
"Aurie is addressing the industry's biggest challenge by combining sustainability and user-centered design to define a new standard of care. The De Novo clearance is a major milestone, and I'm excited to work with this team as they take the business to the next level," said
Dr. Christopher Elliott Joins Scientific Advisory Board
Sergey Grigoryants Promoted to Chief Technology Officer
About Aurie
Aurie is a medical device company that has developed the first safely+ reusable no-touch intermittent catheter system. Aurie has been supported by Lakehouse Ventures, among others. Learn more at livewithaurie.com.
+When used in accordance with the Instructions for Use.
View original content:https://www.prnewswire.com/news-releases/aurie-receives-fda-de-novo-grant-for-first-automated-safely-reusable-intermittent-urinary-catheter-system-302767331.html
SOURCE CathBuddy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boo Bash Fall Festival to Make California Debut September 18, Bringing 100,000+ Square-Foot Immersive Pumpkin Patch to Escondido
- Greenberg Traurig Advises Ryman Hospitality Properties on $1.38B Grande Lakes Orlando Resort Acquisition
- Furnished Quarters Recognized as the Best Corporate Housing Provider in Manhattan
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share